Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas
N/A
N/A
Both
Sarcoma
Trial Information
Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas
OBJECTIVES:
- To investigate whether the expression of a subset of proteins (by
immunohistochemistry), known to be involved in the Pax3, Pax7, and Patched-1
neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar
and embryonal rhabdomyosarcomas.
OUTLINE: Iimmunohistochemistry is performed for each candidate target (Pax3, Pax7, and
Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue
microarray analysis.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- 8 tissue microarrays (TMA) slides of the following diseases available:
- Alveolar rhabdomyosarcoma
- Embryonal rhabdomyosarcoma
- Anaplastic rhabdomyosarcoma
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma
Safety Issue:
No
Principal Investigator
Charles Keller, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Oregon Health and Science University
Authority:
United States: Federal Government
Study ID:
CDR0000738499
NCT ID:
NCT01668095
Start Date:
August 2012
Completion Date:
Related Keywords:
- Sarcoma
- adult rhabdomyosarcoma
- alveolar childhood rhabdomyosarcoma
- embryonal childhood rhabdomyosarcoma
- previously treated childhood rhabdomyosarcoma
- recurrent adult soft tissue sarcoma
- recurrent childhood rhabdomyosarcoma
- stage III adult soft tissue sarcoma
- stage IV adult soft tissue sarcoma
- Rhabdomyosarcoma
- Sarcoma
Name | Location |
|---|
